Feedback

Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis

Affiliation
Beijing University of Chinese Medicine ,Beijing ,China
Deng, Yutong;
Affiliation
Beijing University of Chinese Medicine ,Beijing ,China
Feng, Ruli;
Affiliation
Department of Dermatology ,Dongfang Hospital ,Beijing University of Chinese Medicine ,Beijing ,China
Hu, Bo;
Affiliation
Department of Dermatology ,Shanxi Traditional Chinese Medical Hospital ,Shanxi ,China
Ren, Xuewen;
Affiliation
Department of Dermatology ,Dongfang Hospital ,Beijing University of Chinese Medicine ,Beijing ,China
Zhang, Fengchuan;
Affiliation
Department of Dermatology ,Dongfang Hospital ,Beijing University of Chinese Medicine ,Beijing ,China
Feng, Huishang;
Affiliation
Beijing University of Chinese Medicine ,Beijing ,China
Wang, Xuewan;
Affiliation
Beijing University of Chinese Medicine ,Beijing ,China
Li, Yatong;
Affiliation
Beijing University of Chinese Medicine ,Beijing ,China
Liu, Tangyunni;
Affiliation
Department of Dermatology ,Dongfang Hospital ,Beijing University of Chinese Medicine ,Beijing ,China
Cai, Lingling;
Affiliation
Department of Dermatology ,Dongfang Hospital ,Beijing University of Chinese Medicine ,Beijing ,China
Li, Yuanwen

Objectives To evaluate the efficacy and safety of Tanshinone capsule as a complementary therapy in managing of Acne Vulgaris. Methods A systematic search of six databases was conducted to identify relevant randomized controlled trials (RCTs) from each database for nearly 20 years (from 1 Jan 2004, to 1 June 2024). The Cochrane Handbook was used to evaluate the risk of bias. Meta-analysis was performed using Review Manager 5.4.1, and publication bias was assessed the Stata SE 12.0 software. GRADEpro was used to assess the quality of the evidence. Results A total of 2,969 participants from 28 studies were included. We found that Tanshinone capsules can reduce acne recurrence rates [risk ratio ( RR ) 0.44, 95% confidence interval (CI): 0.34 to 0.57, p < 0.00001]; downregulate levels of necrosis factor-alpha (TNF-α) [ mean difference ( MD ) 0.44, −10.18, 95% CI: −13.57 to −8.04, p < 0.00001], interleukin (IL) 4 ( MD -6.46, 95%CI: −7.14 to −5.77, p < 0.00001), IL-6 ( MD -16.14, 95%CI: −30.10 to −2.18, p = 0.02), IL-8 ( MD -4.48, 95%CI: −8.30 to −0.65, p = 0.02) and testosterone ( MD -14.50, 95%CI: −17.59 to −11.40, p < 0.00001); lower Global Acne Grading System (GAGS) score ( MD -4.71, 95%CI: −7.62 to −1.80, p = 0.002); decrease sebum secretion rates ( MD -0.29, 95%CI: −0.49 to −0.10, p = 0.003), but the regulation of Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), Estradiol (E 2 ) is not obvious. In terms of safety, the incidence of adverse events in the experimental group was less than that in the control group ( RR 0.70, 95%CI: 0.56 to 0.87, p = 0.001). The Begg test and Egger test results indicated no publication bias. Furthermore, the levels of evidence ranged from very low to moderate due to risk of bias and heterogeneity. Conclusion Tanshinone capsules can relieve the symptoms of acne vulgaris, regulate inflammatory cytokines and hormone levels in patients, and reduce recurrence. However, due to the limitations of this study, more multi-center and large-sample studies are needed to confirm these conclusions. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562320 , identifier CRD42024562320.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Deng, Feng, Hu, Ren, Zhang, Feng, Wang, Li, Liu, Cai and Li.

Use and reproduction: